Metabolic Market Intelligence
Obesity, diabetes, NASH/MASH, and lipid disorders including GLP-1 and next-generation metabolic targets.
9
Indications Covered
110+
Competitors Tracked
5
Analysis Modules
Key Indications
Type 2 DiabetesObesityNASH/MASHDyslipidemia
What You Get
Market Sizing
Patient funnel-based TAM/SAM/SOM with biomarker nesting, payer mix, and geographic decomposition.
Competitive Landscape
Threat assessment, displacement risk, mechanism analysis, and patent cliff intelligence.
Partner Analysis
Strategic adjacency scoring across 300+ pharma, biotech, and medtech companies.
Regulatory Pathways
LOA by phase, designation impact, FDA/EMA pathway analysis with timeline estimates.
Live Intelligence
Real-time market signals classified by type — competitive, regulatory, clinical, deal.
PDF Reports
Institutional-grade exportable reports ready for board presentations and partner meetings.